コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ge repair, and mutations in SMCHD1 can cause facioscapulohumeral muscular dystrophy.
2 a phase 3 study of losmapimod in adults with facioscapulohumeral muscular dystrophy.
3 sion, and p38beta MAPK) for the treatment of facioscapulohumeral muscular dystrophy.
4 ate the degree of pathology in patients with facioscapulohumeral muscular dystrophy.
5 on chromosome 4 that is partially deleted in facioscapulohumeral muscular dystrophy.
6 wn-regulation of ALP does not participate in facioscapulohumeral muscular dystrophy.
7 e 4q35 and was identified as a candidate for facioscapulohumeral muscular dystrophy.
8 muscles with iliopsoas sparing is common in facioscapulohumeral muscular dystrophy (67% of the patie
9 ations of chromatin structure: ICF syndrome, facioscapulohumeral muscular dystrophy and a case of alp
10 ancer, Scissor was effective in interpreting facioscapulohumeral muscular dystrophy and Alzheimer's d
11 ular dystrophy: Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dys
12 are consistent with a model that configures facioscapulohumeral muscular dystrophy as a "muscle-by-m
13 it also results in enhanced silencing at the facioscapulohumeral muscular dystrophy associated macros
14 nvolvement of fibroadipogenic progenitors in facioscapulohumeral muscular dystrophy.Facioscapulohumer
15 scle MRI can be also used for distinguishing facioscapulohumeral muscular dystrophy from other myopat
17 strate that cells derived from patients with facioscapulohumeral muscular dystrophy (FSHD) activate h
19 the D4Z4 copy numbers, a known biomarker for facioscapulohumeral muscular dystrophy (FSHD) and estima
20 mbryos, whereas misexpression of DUX4 causes facioscapulohumeral muscular dystrophy (FSHD) and is ass
21 ng valid approaches for genetic diagnosis in facioscapulohumeral muscular dystrophy (FSHD) and MUC1-a
23 Advances in the molecular understanding of facioscapulohumeral muscular dystrophy (FSHD) have revea
73 ce places the subtelomeric defect underlying facioscapulohumeral muscular dystrophy (FSHD) much close
74 sion in skeletal muscles plays a key role in facioscapulohumeral muscular dystrophy (FSHD) pathogenes
77 ons in SMCHD1 that have been associated with facioscapulohumeral muscular dystrophy (FSHD) type 2.
78 subtelomeric region of chromosome 4q causes facioscapulohumeral muscular dystrophy (FSHD) when occur
79 ms, and its aberrant expression is linked to facioscapulohumeral muscular dystrophy (FSHD) where it h
81 ubtelomeric region, 4q35.2, is implicated in facioscapulohumeral muscular dystrophy (FSHD), a dominan
82 deformation (strain) in patients affected by facioscapulohumeral muscular dystrophy (FSHD), a prevale
83 c transcription factor and causative gene of facioscapulohumeral muscular dystrophy (FSHD), induces t
86 ce best supports an epigenetic mechanism for facioscapulohumeral muscular dystrophy (FSHD), whereby d
96 beginning of this disease-associated array (facioscapulohumeral muscular dystrophy, FSHD) despite se
98 olemma of skeletal muscle from patients with facioscapulohumeral muscular dystrophy (FSHD1A) to learn
99 ted with the age-associated genetic disease, facioscapulohumeral muscular dystrophy (FSHD1A, MIM 1589
100 shed SMCHD1 function in muscle fibers causes Facioscapulohumeral Muscular Dystrophy (FSHD2) through d
101 included adults aged 18-65 years with type 1 facioscapulohumeral muscular dystrophy (ie, with loss of
102 5 near the heterochromatic region mutated in facioscapulohumeral muscular dystrophy, indicating a pos
105 he validity of the human graft as a model of facioscapulohumeral muscular dystrophy is demonstrated i
106 dystrophy (DMD), Becker muscular dystrophy, facioscapulohumeral muscular dystrophy, limb-girdle musc
108 most frequent are the dystrophinopathies and facioscapulohumeral muscular dystrophy making up 22.9% (
109 fficient, and use this finding to develop an facioscapulohumeral muscular dystrophy mouse model with
110 of disease, iMyoblasts from individuals with Facioscapulohumeral Muscular Dystrophy revealed a previo
112 lated to be affected by mutations that cause facioscapulohumeral muscular dystrophy; thus, the charac